Drug Trial Radar · NCT02856113
Phase 3 Alogliptin Pediatric Study
Last checked: Nov 19, 2026Latest source record: Oct 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Oct 14, 2016
Primary completion
Aug 6, 2021
Study completion Feb 14, 2022
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Aug 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric participants with type 2 diabetes mellitus (T2DM).
Conditions
- Diabetes Mellitus, Type 2
Interventions
Alogliptin BenzoateDrug
Alogliptin benzoate tablets.
PlaceboDrug
Alogliptin placebo-matching tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26Time frame: Baseline and Week 26
Locations
67 sites in 7 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital Research Institute
Little Rock, Arkansas
Children's Hospital Los Angeles
Los Angeles, California
Sherif Khamis
Palmdale, California
Lucile Packard Children's Hospital at Stanford University
Palo Alto, California
Touro University California
Vallejo, California
Yale New Haven Hospital
New Haven, Connecticut
Children's National Health System
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
Nemours Childrens Specialty Care - Jacksonville
Jacksonville, Florida
Baptist Diabetes Associates Research
Miami, Florida
University of South Florida/USF Health
Tampa, Florida
Endocrine Consultants Research
Columbus, Georgia
Endocrine Consultants Research - Oak Hill Court
Newnan, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Kentucky Health Care
Lexington, Kentucky
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Ochsner Baptist Medical Center
New Orleans, Louisiana
University of Minnesota Masonic Children's Hospital - Pediatric Specialty Care Discovery Clinic
Minneapolis, Minnesota
Gulfside Clinical Research
Gulfport, Mississippi
Saint Louis University
St Louis, Missouri
Horizon View Medical Center
Las Vegas, Nevada
Saint Joseph's Regional Medical Center - Paterson
Paterson, New Jersey
University of Rochester
Rochester, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Greenville Health System - Patewood
Greenville, South Carolina
Monument Health Clinical Research
Rapid City, South Dakota
UT Le Bonheur Pediatric Specialists
Memphis, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine Advanced Liver Therapies
Houston, Texas
University of Virginia
Charlottesville, Virginia
Seattle Children's Hospital
Seattle, Washington
Multicare Health System Institute for Research and Innovation
Tacoma, Washington
Hospital Sirio Libanes
São Paulo, Brazil
Instituto de Estudos e Pesquisas Clinicas do Ceara
Fortaleza, Ceará, Brazil
Hospital Universitario Joao de Barros Barreto
Belém, Pará, Brazil
Instituto da Crianca com Diabetes
Porto Alegre, Rio Grande do Sul, Brazil
Hadassah University Hospital Mount Scopus
Jerusalem, Israel
Clalit Medical Center
Tel Aviv, Israel
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.